David L. Tait

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

Rhea N. Coler, Tracey A. Day, Ruth D. Ellis et al. · npj Vaccines · 2018 · 164 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.

David L. Tait, Patrice S. Obermiller, A R Hatmaker et al. · PubMed · 1999 · 72 citations

Medicine, Immunology, Oncology +17

A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer.

David L. Tait, Patrice S. Obermiller, S Redlin-Frazier et al. · PubMed · 1997 · 66 citations

Medicine, Oncology, Pharmacokinetics +14

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Julie Gottlieb Fisher, David L. Tait, Elizabeth Garrett‐Mayer et al. · Targeted Oncology · 2020 · 47 citations

Medicine, Oncology, Pharmacology +17

When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer

Jubilee Brown, Lane Drury, Erin K. Crane et al. · Journal of Minimally Invasive Gynecology · 2018 · 43 citations

Medicine, Oncology, Surgery +17